FDA 483, dated June 11, 2008, (9 pages)
Similar Posts
Alembic Pharmaceuticals Limited – 02/06/2021
Alembic Pharmaceuticals Limited – 02/06/2021. Country: India. Record Type: 483FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
FDA approved the first rapid-acting biosimilar insulin product, Merilog (insulin-aspart-szij), a biosimilar to its reference product Novolog (insulin aspart), to improve glycemic control in adults and children with diabetes mellitus.mRNA COVID-19 Vaccines: FDA Safety Communication – FDA Approves Required Updated Warning in Labeling Regarding Myocarditis and Pericarditis Following Vaccination
mRNA COVID-19 Vaccines: FDA Safety Communication – FDA Approves Required Updated Warning in Labeling Regarding Myocarditis and Pericarditis Following VaccinationHoward I. Schwartz, M.D. Hollywood, FL. EIR issued 11/19/2020
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/19/2020
Short Title (70 char) Howard I. Schwartz, M.D. Hollywood, FL. EIR issued 11/19/2020
FEI Number 1000525885
Firm Name Howard I. Schwartz, M.D.
Record Type EIR
State FL
Establishment Type Clinical InvestDrug Shortages
Drug Shortages HomepageReal-World Evidence Submissions to the Center for Drug Evaluation and Research
As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA VII), FDA committed to reporting aggregate and anonymized information on submissions.